[144] Enova International, Inc. SEC Filing

Rhea-AI Filing Summary

Enova International insider sale notice under Rule 144: The filing reports a proposed sale of 15,000 shares of Enova common stock through Merrill Lynch on or about 08/28/2025, with an aggregate market value of $1,815,000 (implying $121.00 per share). The shares were acquired on 02/12/2019 via stock options granted by Enova International. The filer, identified in related sales as David Fisher at a Chicago address, sold 2,000 shares on 06/20/2025, 5,000 on 07/14/2025, and 5,000 on 08/28/2025 for total gross proceeds of $1,361,515.97. The company has 25,012,613 shares outstanding per the form. The signer certifies no undisclosed material adverse information and references Rule 10b5-1 compliance language.

Positive

• Filing provides clear transaction details including broker, share counts, dates, and aggregate values
• Acquisition method disclosed (stock options acquired 02/12/2019), supporting Rule 144 provenance
• Signer certifies no undisclosed material adverse information, aligning with disclosure norms

Negative

• Significant insider sales activity: 12,000 shares sold in the past three months with an additional 15,000 proposed sale
• Sale represents insider liquidity that investors may view negatively absent explanatory context
• No 10b5-1 plan adoption date provided in the filing, though the form references such plans

Insights

Securities Analyst

TL;DR: Insider sales totaling 12,000 shares already executed with an additional 15,000-share notice; routine disclosure, likely neutral to modestly negative.

The filing documents routine compliance with Rule 144 for the proposed sale of 15,000 shares acquired by stock options in 2019. Recent sales by the same person (2,000; 5,000; 5,000) generated roughly $1.36 million in gross proceeds. For a company with 25.0 million shares outstanding, these transactions are small relative to total float and do not alone indicate material corporate change. Investors typically note insider sales as a data point; absent corroborating operational or financial signals in this form, the disclosure is procedural rather than catalytic.

Corporate Governance Expert

TL;DR: The notice appears procedurally complete and includes the standard signer certification; no governance red flags shown.

The form specifies acquisition via stock options and lists broker and sale schedule details consistent with Rule 144 requirements. The signer affirms lack of undisclosed material adverse information and references potential 10b5-1 plan adoption, though no plan date is provided. From a governance perspective, the filing fulfills disclosure obligations; it does not provide evidence of insider trading irregularities or required remediation actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 110 N Wacker Dr Ste 1900 Chicago IL 60606	15000	1815000.00	25012613	08/28/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/12/2019	Stock Options	Enova International			15000	02/12/2019	Stock Option

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Fisher 175 West Jackson Blvd, Suite 600 Chicago IL 60604	Common	06/20/2025	2000	196762.87
David Fisher 175 West Jackson Blvd Suite 600 Chicago IL 60604	Common	07/14/2025	5000	575951.66
David Fisher 175 West Jackson Blvd Suite 600 Chicago IL 60604	Common	08/28/2025	5000	588801.44

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Enova (ENVA) Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 15,000 common shares through Merrill Lynch on or about 08/28/2025 with an aggregate market value of $1,815,000.

Who acquired the shares and how were they acquired?

The shares were acquired on 02/12/2019 via stock options granted by Enova International.

How many shares has the filer sold recently and for how much?

The filer sold 2,000 shares on 06/20/2025, 5,000 on 07/14/2025, and 5,000 on 08/28/2025, generating gross proceeds of $196,762.87, $575,951.66, and $588,801.44 respectively (total $1,361,515.97).

How many Enova shares are outstanding according to the filing?

The form lists 25,012,613 shares outstanding.

Does the filing state there is undisclosed adverse information?

The signer represents by signing the notice that they do not know any undisclosed material adverse information regarding the issuer.